We offer an equity analysis subscription service inducing; nightly email, SMS alerts, in depth research reports on conviction plays, education and more. See our full offerings here and join the community with a free trial!
- ZSAN is a clinical-stage biotech company focused on developing therapeutics and other bioactive molecules through its “intracutaneous microneedle patch system“
- ZSAN is nearing a resubmission for a new drug application (NDA) for its lead asset- Qtrypa patch (M207) as an acute migraine treatment
- To read the clinical data for M207 so far click here
- Its second asset (C213) is in P2 of development to treat cluster headaches